(HIMS) Hims Hers Health - Ratings and Ratios
Wellness, Skincare, SexualHealth, HairCare, Supplements, PrescriptionMedication
HIMS EPS (Earnings per Share)
HIMS Revenue
Description: HIMS Hims Hers Health
Hims & Hers Health, Inc. is a telehealth company that connects consumers with licensed healthcare professionals and offers a range of health and wellness products, including prescription medication, over-the-counter products, and supplements. The companys platform is available in multiple countries, and its products cater to various health categories, such as general wellness, sexual health, skincare, and hair care.
From a business perspective, Hims & Hers Health has demonstrated significant growth, with a strong brand presence in the telehealth industry. To evaluate the companys performance, key metrics to consider include revenue growth rate, customer acquisition cost, and customer retention rate. The companys ability to expand its product offerings and geographic reach will be crucial in driving future growth.
Analyzing the companys financials, we can see that Hims & Hers Health has a market capitalization of $11.2 billion, indicating a substantial presence in the healthcare services sector. The price-to-earnings ratio of 73.51 suggests that the stock may be overvalued, while the forward P/E ratio of 40.32 indicates potential for future earnings growth. Return on Equity (RoE) of 35.97% is a positive indicator of the companys profitability.
To further assess the companys prospects, it is essential to monitor key performance indicators (KPIs) such as monthly active users, conversion rates, and average order value. Additionally, the competitive landscape and regulatory environment in the telehealth industry should be closely watched, as they may impact Hims & Hers Healths growth trajectory.
HIMS Stock Overview
| Market Cap in USD | 11,265m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2019-09-13 |
HIMS Stock Ratings
| Growth Rating | 84.9% |
| Fundamental | 75.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 179% |
| Analyst Rating | 3.46 of 5 |
HIMS Dividends
Currently no dividends paidHIMS Growth Ratios
| Growth Correlation 3m | -25.1% |
| Growth Correlation 12m | 81.1% |
| Growth Correlation 5y | 52.6% |
| CAGR 5y | 112.03% |
| CAGR/Max DD 3y | 1.77 |
| CAGR/Mean DD 3y | 4.91 |
| Sharpe Ratio 12m | 1.68 |
| Alpha | 233.93 |
| Beta | 0.924 |
| Volatility | 82.92% |
| Current Volume | 25530.4k |
| Average Volume 20d | 24709.6k |
| Stop Loss | 50.1 (-7.2%) |
| Signal | 0.20 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (193.6m TTM) > 0 and > 6% of Revenue (6% = 120.8m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -12.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 53.80% (prev 17.08%; Δ 36.72pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 261.6m > Net Income 193.6m (YES >=105%, WARN >=100%) |
| Net Debt (-80.2m) to EBITDA (154.8m) ratio: -0.52 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.98 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (256.8m) change vs 12m ago 9.36% (target <= -2.0% for YES) |
| Gross Margin 76.20% (prev 82.19%; Δ -5.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 170.8% (prev 222.1%; Δ -51.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 4.12
| (A) 0.58 = (Total Current Assets 1.36b - Total Current Liabilities 272.2m) / Total Assets 1.88b |
| (B) -0.08 = Retained Earnings (Balance) -150.1m / Total Assets 1.88b |
| (C) 0.11 = EBIT TTM 125.6m / Avg Total Assets 1.18b |
| (D) -0.11 = Book Value of Equity -149.3m / Total Liabilities 1.31b |
| Total Rating: 4.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.85
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 1.08% = 0.54 |
| 3. FCF Margin 5.94% = 1.48 |
| 4. Debt/Equity 1.73 = 1.17 |
| 5. Debt/Ebitda 6.28 = -2.50 |
| 6. ROIC - WACC 24.06% = 12.50 |
| 7. RoE 38.17% = 2.50 |
| 8. Rev. Trend 98.78% = 7.41 |
| 9. EPS Trend 84.99% = 4.25 |
What is the price of HIMS shares?
Over the past week, the price has changed by +8.70%, over one month by +17.25%, over three months by -9.74% and over the past year by +231.45%.
Is Hims Hers Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HIMS is around 61.94 USD . This means that HIMS is currently undervalued and has a potential upside of +14.79% (Margin of Safety).
Is HIMS a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 6
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the HIMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.5 | -8.4% |
| Analysts Target Price | 49.5 | -8.4% |
| ValueRay Target Price | 69.6 | 29.1% |
Last update: 2025-09-13 05:03
HIMS Fundamental Data Overview
CCE Cash And Equivalents = 1.14b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 60.8941
P/E Forward = 62.1118
P/S = 5.5947
P/B = 19.1919
P/EG = 5.2308
Beta = 2.136
Revenue TTM = 2.01b USD
EBIT TTM = 125.6m USD
EBITDA TTM = 154.8m USD
Long Term Debt = 969.5m USD (from longTermDebt, last quarter)
Short Term Debt = 3.13m USD (from shortTermDebt, last quarter)
Debt = 972.6m USD (Calculated: Short Term 3.13m + Long Term 969.5m)
Net Debt = -80.2m USD (from netDebt column, last quarter)
Enterprise Value = 11.09b USD (11.27b + Debt 972.6m - CCE 1.14b)
Interest Coverage Ratio = unknown (Ebit TTM 125.6m / Interest Expense TTM 0.0)
FCF Yield = 1.08% (FCF TTM 119.5m / Enterprise Value 11.09b)
FCF Margin = 5.94% (FCF TTM 119.5m / Revenue TTM 2.01b)
Net Margin = 9.62% (Net Income TTM 193.6m / Revenue TTM 2.01b)
Gross Margin = 76.20% ((Revenue TTM 2.01b - Cost of Revenue TTM 479.2m) / Revenue TTM)
Tobins Q-Ratio = -74.30 (set to none) (Enterprise Value 11.09b / Book Value Of Equity -149.3m)
Interest Expense / Debt = 0.16% (Interest Expense 1.58m / Debt 972.6m)
Taxrate = -75.76% (set to none) (-54.3m / 71.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 4.98 (Total Current Assets 1.36b / Total Current Liabilities 272.2m)
Debt / Equity = 1.73 (Debt 972.6m / last Quarter total Stockholder Equity 562.7m)
Debt / EBITDA = 6.28 (Net Debt -80.2m / EBITDA 154.8m)
Debt / FCF = 8.14 (Debt 972.6m / FCF TTM 119.5m)
Total Stockholder Equity = 507.2m (last 4 quarters mean)
RoA = 10.31% (Net Income 193.6m, Total Assets 1.88b )
RoE = 38.17% (Net Income TTM 193.6m / Total Stockholder Equity 507.2m)
RoCE = 8.51% (Ebit 125.6m / (Equity 507.2m + L.T.Debt 969.5m))
RoIC = 24.06% (Ebit 125.6m / (Assets 1.88b - Current Assets 1.36b))
WACC = unknown (E(11.27b)/V(12.24b) * Re(9.42%)) + (D(972.6m)/V(12.24b) * Rd(0.16%) * (1-Tc(none)))
Shares Correlation 3-Years: 96.97 | Cagr: 2.06%
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 70.58% ; FCFE base≈107.5m ; Y1≈92.3m ; Y5≈72.1m
Fair Price DCF = 4.80 (DCF Value 1.04b / Shares Outstanding 217.6m; 5y FCF grow -17.25% → 3.0% )
EPS Correlation: 84.99 | EPS CAGR: 0.0% | SUE: 0.18 | # QB: False
Revenue Correlation: 98.78 | Revenue CAGR: 61.89%
Additional Sources for HIMS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle